These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 18721669

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
    Ozen ME, Yumru M, Savas HA, Cansel N, Herken H.
    World J Biol Psychiatry; 2007; 8(1):42-4. PubMed ID: 17366349
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Evidence for Pavlovian conditioning of cocaine-induced responses linked to emotional behavioral effects.
    Carey RJ, DePalma G, Damianopoulos E.
    Pharmacol Biochem Behav; 2005 Jan; 80(1):123-34. PubMed ID: 15652388
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Ziprasidone: a novel psychotropic with unique properties.
    Ballas C, Yang C, O'Reardon J, Ballas P, Baldassano C.
    Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
    [Abstract] [Full Text] [Related]

  • 51. Ziprasidone--not haloperidol--induces more de-novo neurogenesis of adult neural stem cells derived from murine hippocampus.
    Benninghoff J, Grunze H, Schindler C, Genius J, Schloesser RJ, van der Ven A, Dehning S, Wiltfang J, Möller HJ, Rujescu D.
    Pharmacopsychiatry; 2013 Jan; 46(1):10-5. PubMed ID: 22592505
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Haloperidol treatment reverses behavioural and anatomical changes in cocaine-dependent mice.
    Parish CL, Drago J, Stanic D, Borrelli E, Finkelstein DI, Horne MK.
    Neurobiol Dis; 2005 Jan; 19(1-2):301-11. PubMed ID: 15837586
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.
    Moreira FA, Guimarães FS.
    Eur J Pharmacol; 2005 Apr 11; 512(2-3):199-205. PubMed ID: 15840405
    [Abstract] [Full Text] [Related]

  • 58. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
    Harvey PD, Endicott JM, Loebel AD.
    Bipolar Disord; 2008 Dec 11; 10(8):900-6. PubMed ID: 19594505
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Leuprolide: a luteinizing hormone releasing hormone agonist attenuates ethanol withdrawal syndrome and ethanol-induced locomotor sensitization in mice.
    Umathe SN, Bhutada PS, Dixit PV, Jain NS.
    Neuropeptides; 2008 Jun 11; 42(3):345-53. PubMed ID: 18280564
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.